Clinical trial
Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of…
NCT00001984 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00001984 |
|---|---|
| Title | Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys |
| Official title | Tolerance Induction Following Human Renal Transplantation Using Treatment With a Humanized Monoclonal Antibody Against CD52 (Campath-1H) |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Rejection, Kidney Disease |
| Intervention type | Drug |
| Interventions | Alemtuzumab and DSG |
| Enrollment | 5 |
| Start date | Nov 1, 1999 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jan 27, 2000 |
| Last update posted | Oct 27, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: